Quick Takeaways
- BML Investment Partners, L.P. filed SCHEDULE 13D/A for AN2 Therapeutics, Inc. Common Stock, par value $0.00001 per share (ANTX).
- Disclosed ownership: 1.4%.
- Date of event: 17 Jun 2025.
BML Investment Partners, L.P. - 17 Jun 2025 SCHEDULE 13D/A Report for AN2 Therapeutics, Inc. Common Stock, par value $0.00001 per share (ANTX)
- Filing Manager
- BML Investment Partners, L.P.
- Reporting Manager
- BML Investment Partners, L.P.
- Symbol
- ANTX
- Shares outstanding
- 30,530,857 shares
- Disclosed Ownership
- 427,432 shares
- Ownership
- 1.4%
- Form type
- SCHEDULE 13D/A
- Filing time
- 18 Jun 2025, 11:08:01 UTC
- Date of event
- 17 Jun 2025
- Previous filing
- 30 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BML Investment Partners, L.P. disclosed 1.4% ownership in AN2 Therapeutics, Inc. Common Stock, par value $0.00001 per share (ANTX) on 17 Jun 2025."
What Changed
- Previous schedule filing date: 30 May 2025.
- Current filing was accepted on 18 Jun 2025, 11:08.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BML Investment Partners, L.P. | 1.4% | 427,432 | 0 | 427,432 | Braden M Leonard | Braden M Leonard - Managing Member of BML Capital Management, LLC | 0001373604 |